Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07494968

Defining Objective Markers of Compliance for Dietary Therapies in IBS

This research will investigate if a specific marker in your stool or urine can be used to track changes in your carbohydrate intake including fructo-oligosaccharide and mannitol intake

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location status: Recruiting

Location contact

Allen Lee, MD, MS

SUB_INVESTIGATOR

Prashant Singh, MBBS

CONTACT

[email protected]

734-647-9252

Prashant Singh, MBBS

PRINCIPAL_INVESTIGATOR

About this study

The primary purpose of this study is to evaluate if an objective biomarker can be used to evaluate the amount of specific carbohydrate intake. It is to measure the coloration between Gluten immunogenic Peptides (GIP) and fructo-oligosaccharide intake(on 24-hour diet recall) at Week 4 to identify an objective biomarker for dietary content evaluation which is critical for dietary treatment.

The researchers hope GIP can be used to evaluate the amount of carbohydrate intake in clinical practice.)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with IBS ( including diarrhea, mixed or constipation type) and without unexplained alarm features (rectal bleeding, weight loss, nocturnal pain, nocturnal diarrhea). In presence of alarm symptoms, if they have had evaluation with colonoscopy or fecal calprotectin or serum C-reactive protein (CRP) since onset of alarm symptoms with normal results, they will be included.
  • Aged 18-65 years at the time of screening
  • IBS-SSS of at least 175 at baseline

Exclusion criteria

  • Subjects adhering to a dietary treatment such as the low-fat diet, low FODMAP diet, or gluten-free diet, within the past 6 months. Those who are lactose intolerant will not be excluded from the study and will be allowed to limit lactose intake as previously.
  • Subjects who are predicted to make changes to their baseline IBS medication(s), over-the-counter (OTC) therapy, exercise, diet (beyond what is advised), or initiate/make changes to other complementary therapy that could affect IBS symptoms (e.g. yoga, acupuncture, etc.) during the four weeks study period.
  • Subjects with a known history of celiac disease, inflammatory bowel disease or microscopic colitis
  • Subjects with a history of an eating disorder requiring medical or behavioral treatment within the past 10 years.
  • BMI < 18.5
  • Subjects with prior small bowel or colonic surgery (other than appendectomy or cholecystectomy).
  • History of appendectomy or cholecystectomy in the last 6 months.
  • Oral antibiotic use in the past 3 months
  • Any planned significant changes in dietary or exercise regimen within 30 days prior to Screening or during the study.
  • Currently pregnant or breastfeeding.

Treatment and study plan

Diet A - elimination diet

Behavioral

Combined oligosaccharide intake (fructans plus galacto-oligosaccharides) will be limited to <0.50 grams per serving (same as above), while polyols, lactose, and fructose will not be limited.

Diet B - healthy eating diet

Behavioral

The subjects will be instructed to regularly eat 3 meals and 3 snacks a day, never too much or too little each time, never to be hungry or too full; to eat in peace and quiet and to chew thoroughly; drinks at least 8 cups of fluids a day, reduce intake of fatty or spicy foods, coffee, alcohol; avoid soft drinks and carbonated beverages, chewing gums, and sweeteners that ends with -ol, and to eat fibers with focus on soluble fibers such as oats but distribute the intake evenly during the day

Primary outcomes

  1. Correlation between fecal GIP excretion and fructo-oligosaccharide intake

    Time frame: Week 4

    Assessed using 24-hour recall

Secondary outcomes

  1. The Irritable Bowel Severity Scoring System (IBS-SSS) score

    Time frame: Week 4

    The Irritable Bowel Severity Scoring System (IBS-SSS) is a questionnaire used for evaluating the severity of IBS with a maximum score of 500. Higher scores indicate increased pain.

  2. Patient-Reported Outcomes Measurement Information System (PROMIS) abdominal pain score

    Time frame: Week 4

    PROMIS abdominal pain scores are assessed using the PROMIS Belly Pain 5a which range from 5-25 and higher scores indicate worse symptoms.

  3. PROMIS bloating score

    Time frame: Week 4

    PROMIS bloating scores are assessed using the PROMIS Gas and Bloating 13a (PROGB has 13 questions with scores ranging from 12-60. Higher scores indicate worse symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Prashant Singh, MBBS

CONTACT

[email protected]

734-647-9252

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Registry information

Official study title

Defining Objective Markers of Compliance for Dietary Therapies in Irritable Bowel Syndrome (IBS) Using a Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 27, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.